Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153565 | 0.91 | SIGMAR1 (0.59) | SIGMAR1MCHR1ALDH1A1KDM4EGAA | |
| SCHEMBL6154032 | 0.86 | SLC6A12 (0.56) | SIGMAR1MCHR1KDM4EGAATSHR | |
| SCHEMBL8487979 | 0.83 | ACHE (0.69) | SIGMAR1ALDH1A1KDM4EGAAHSD17B10 | |
| SCHEMBL18033383 | 0.82 | HCAR3 (0.58) | ALDH1A1KDM4ETSHRRAB9A | |
| SCHEMBL5118863 | 0.81 | KDM4E (0.54) | SIGMAR1MCHR1ALDH1A1KDM4EGAA | |
| SCHEMBL6154872 | 0.81 | MEN1 (0.56) | SIGMAR1MCHR1ALDH1A1KDM4EGAA | |
| SCHEMBL2390512 | 0.80 | KMT2A (0.70) | SIGMAR1MCHR1ALDH1A1KDM4EDRD4 | |
| SCHEMBL1789399 | 0.80 | MCHR1 (0.76) | SIGMAR1MCHR1TSHRDRD2DRD4 | |
| SCHEMBL12427426 | 0.80 | DRD4 (0.69) | SIGMAR1MCHR1DRD2DRD4DRD3 | |
| SCHEMBL6153423 | 0.79 | MCHR1 (0.62) | SIGMAR1MCHR1TSHRLTA4HDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | SIGMAR1 695/4885MCHR1 1952/4885ALDH1A1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.